← Leaderboards
Michael John Palladino
University Of Pittsburgh At Pittsburgh
$10,111,937
Attributed
$12,854,970
Total exposure
16
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,854,970 · 16
By mechanism
R01$10,775,590 · 7
R21$1,706,182 · 4
R25$177,267 · 1
R03$157,750 · 1
P41$38,181 · 3
Top collaborators
- Andreas Vogt10 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Andreas Vogt$5,634,005
- Roy A Mariuzza$20,943,458
- Matthew L Macdonald$4,166,263
- Tina R Goldstein$16,611,129
- Quasar S Padiath$5,958,511
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantMutationDrosophila GenusGeneticProteinsIn VivoLongevityCellsBaseFunctional DisorderPathway InteractionsExhibitsPathogenesisMediatingAffectBiochemicalGenesMissense MutationNeurologicImpairmentAnimalsMolecularMulticatalytic Endopeptidase ComplexPremature
Grant awards (42)
High-content screening for TPI Deficiency therapeutics$548,111
R01 · FY2025 · HD · contact PI
Developing the first TPI Df therapeutics$524,864
R01 · FY2025 · HD · contact PI
Mechanisms of Circadian Rhythm Modulation by Metabolic Disease and Dietary Therapy$357,750
R01 · FY2025 · NS · contact PI
High-content screening for TPI Deficiency therapeutics$550,305
R01 · FY2024 · HD · contact PI
Developing the first TPI Df therapeutics$526,383
R01 · FY2024 · HD · contact PI
Mechanisms of Circadian Rhythm Modulation by Metabolic Disease and Dietary Therapy$397,500
R01 · FY2024 · NS · contact PI
High-content screening for TPI Deficiency therapeutics$543,301
R01 · FY2023 · HD · contact PI
Developing the first TPI Df therapeutics$538,538
R01 · FY2023 · HD · contact PI
High-content screening for TPI Deficiency therapeutics$589,328
R01 · FY2022 · HD · contact PI
Developing the first TPI Df therapeutics$543,231
R01 · FY2022 · HD · contact PI
High-content screening for TPI Deficiency therapeutics$578,477
R01 · FY2021 · HD · contact PI
Developing the first TPI Df therapeutics$543,529
R01 · FY2021 · HD · contact PI
Developing a murine TPI Df model$157,750
R03 · FY2021 · NS · contact PI
Regulators of cytosolic protein quality control in aging and disease$201,707
R21 · FY2019 · AG · contact PI
Genetic modulation of mitochondrial function$195,625
R21 · FY2019 · AG · contact PI
Pre-clinical studies of novel mitochondrial gene therapies$286,768
R01 · FY2018 · GM · contact PI
Regulators of cytosolic protein quality control in aging and disease$240,977
R21 · FY2018 · AG · contact PI
Genetic modulation of mitochondrial function$234,376
R21 · FY2018 · AG · contact PI
Pre-clinical studies of novel mitochondrial gene therapies$286,938
R01 · FY2017 · GM · contact PI
Pre-clinical studies of novel mitochondrial gene therapies$287,103
R01 · FY2016 · GM · contact PI
Determining the cellular and molecular basis of mitochondrial encephalomyopathy seizures$192,500
R21 · FY2016 · NS · contact PI
Pre-clinical studies of novel mitochondrial gene therapies$287,263
R01 · FY2015 · GM · contact PI
Protein quality control mechanisms of novel soluble substrates$286,882
R01 · FY2015 · GM · contact PI
Determining the cellular and molecular basis of mitochondrial encephalomyopathy seizures$231,000
R21 · FY2015 · NS · contact PI
Protein quality control mechanisms of novel soluble substrates$20,533
R01 · FY2015 · GM · contact PI
Protein quality control mechanisms of novel soluble substrates$285,158
R01 · FY2014 · GM · contact PI
Protein quality control mechanisms of novel soluble substrates$276,328
R01 · FY2013 · GM · contact PI
Mitochondrial RNA transport as a novel therapy$182,747
R21 · FY2013 · NS · contact PI
Protein quality control mechanisms of novel soluble substrates$293,620
R01 · FY2012 · GM · contact PI
Mitochondrial RNA transport as a novel therapy$227,250
R21 · FY2012 · NS · contact PI
Mitochondrial Dysfunction and Progressive Encephalomyopathies$378,750
R01 · FY2010 · AG · contact PI
Understanding the Mechanisms of Neuropathogenesis$286,788
R01 · FY2010 · AG · contact PI
Mitochondrial Dysfunction and Progressive Encephalomyopathies$378,750
R01 · FY2009 · AG · contact PI
Understanding the Mechanisms of Neuropathogenesis$289,685
R01 · FY2009 · AG · contact PI
Understanding the Mechanisms of Neuropathogenesis$289,685
R01 · FY2008 · AG · contact PI
PITT-SPURG Summer Program for Undergrad Research Growth$88,995
R25 · FY2008 · GM · contact PI
TEM TOMOGRAPHY OF A DROSOPHILA ATP6 MUTATION$11,116
P41 · FY2008 · RR · contact PI
Understanding the Mechanisms of Neuropathogenesis$295,597
R01 · FY2007 · AG · contact PI
PITT-SPURG Summer Program for Undergrad Research Growth$88,272
R25 · FY2007 · GM · contact PI
TEM TOMOGRAPHY OF A DROSOPHILA ATP6 MUTATION$4,583
P41 · FY2007 · RR · contact PI
Understanding the Mechanisms of Neuropathogenesis$304,425
R01 · FY2006 · AG · contact PI
TEM TOMOGRAPHY OF A DROSOPHILA ATP6 MUTATION$22,482
P41 · FY2006 · RR · contact PI